Alitair Pharmaceuticals, Inc. Company Profile
Alitair Pharmaceuticals, Inc. discovers, invents, and develops medicines for the treatment of respiratory illnesses. Alitair has out-licensed two prescription cough candidates that use its proprietary ion-exchange resin technology, REA™, and other product candidates are available for out-licensing. Additional information about Alitair is available on the Alitair website at www.alitair.com.
News Articles
Alitair to sell two ion-exchange resin patents
US-based Alitair Pharmaceuticals has retained Finn, Warnke & Gayton to sell two Alitair patents and an associated royalty stream at a sealed bid sale on 24 May 2013.
Alitair Offers Benzonatate Formulation with Rx-to-OTC Switch Potential
Alitair Pharmaceuticals, Inc., an early stage pharmaceutical company with multiple respiratory product candidates in development, today provided additional details regarding its â...
Alitair benzonatate formulation now eligible for Rx-to-OTC switch
Early stage pharmaceutical company Alitair Pharmaceuticals will offer benzonatate formulation with Rx-to-OTC switch potential.
Alitair Announces Notice of Patent Allowance for Safer Formulation of Benzonatate
Alitair Pharmaceuticals, Inc., today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its ion exchange resin formula...
USPTO grants NOA to Alitair resin-formulated cough product
The US Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to Alitair Pharmaceuticals' ion exchange resin formulation of benzonatate, a non-narcotic prescription cough product.
Alitair Announces Issuance of Patent Covering its Safer Formulation of Benzonatate
Alitair Pharmaceuticals, Inc., an early stage pharmaceutical company focused on respiratory health, today announced the issuance of U.S. Patent No. 8,357,398. This is the second p...
Alitair Offers Patented IER Formulations with Intrinsic Abuse Deterrence Properties
Alitair Pharmaceuticals, Inc., an early stage pharmaceutical company with multiple respiratory product candidates in development, today provided additional details regarding its '...
Alitair Offers Two Ion-Exchange Resin Patents at a Sealed Bid Sale
Alitair Pharmaceuticals, Inc., an early stage pharmaceutical company with multiple respiratory product candidates in development, today announced that it has retained Finn, Warnke...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
Alitair Pharmaceuticals, Inc. discovers, invents, and develops medicines for the treatment of respiratory illnesses. Alitair has out-licensed two prescription cough candidates tha...
More Information about "Alitair Pharmaceuticals, Inc." on BioPortfolio
We have published hundreds of Alitair Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Alitair Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Alitair Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alitair Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Alitair Pharmaceuticals, Inc. Drugs and Medications on this site too.
